[go: up one dir, main page]

DK2167963T3 - Polymerbærere til immunhistokemi og in situ-hybridisering - Google Patents

Polymerbærere til immunhistokemi og in situ-hybridisering Download PDF

Info

Publication number
DK2167963T3
DK2167963T3 DK08754680.0T DK08754680T DK2167963T3 DK 2167963 T3 DK2167963 T3 DK 2167963T3 DK 08754680 T DK08754680 T DK 08754680T DK 2167963 T3 DK2167963 T3 DK 2167963T3
Authority
DK
Denmark
Prior art keywords
immunohistochemistry
situ hybridization
polymer carriers
carriers
polymer
Prior art date
Application number
DK08754680.0T
Other languages
English (en)
Inventor
Jerry W Kosmeder
Casey A Kernag
Donald Johnson
Christopher Bieniarz
Original Assignee
Ventana Med Syst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventana Med Syst Inc filed Critical Ventana Med Syst Inc
Application granted granted Critical
Publication of DK2167963T3 publication Critical patent/DK2167963T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
    • A61K49/0067—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle quantum dots, fluorescent nanocrystals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G01N33/545—Synthetic resin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/587—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/588—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with semiconductor nanocrystal label, e.g. quantum dots

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK08754680.0T 2007-05-23 2008-05-22 Polymerbærere til immunhistokemi og in situ-hybridisering DK2167963T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93154607P 2007-05-23 2007-05-23
PCT/US2008/006591 WO2008153744A2 (en) 2007-05-23 2008-05-22 Polymeric carriers for immunohistochemistry and in situ hybridization

Publications (1)

Publication Number Publication Date
DK2167963T3 true DK2167963T3 (da) 2019-06-24

Family

ID=39765241

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08754680.0T DK2167963T3 (da) 2007-05-23 2008-05-22 Polymerbærere til immunhistokemi og in situ-hybridisering

Country Status (8)

Country Link
US (7) US7985557B2 (da)
EP (2) EP3561513A1 (da)
JP (4) JP2010528285A (da)
AU (1) AU2008262489B2 (da)
CA (1) CA2687178C (da)
DK (1) DK2167963T3 (da)
ES (1) ES2731432T3 (da)
WO (1) WO2008153744A2 (da)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2078197T3 (da) * 2006-11-01 2016-05-23 Ventana Med Syst Inc Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåde til deres fremstilling og anvendelse
EP3561513A1 (en) * 2007-05-23 2019-10-30 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
WO2010094283A1 (en) 2009-02-19 2010-08-26 Dako Denmark A/S Conjugate molecules
JP5836958B2 (ja) 2009-10-20 2015-12-24 ダコ・デンマーク・エー／エス 単独標的実体の免疫化学的検出
ES2621128T3 (es) 2010-02-02 2017-07-03 Ventana Medical Systems, Inc. Composición y procedimiento para la estabilización de partículas fluorescentes
US8377672B2 (en) * 2010-02-18 2013-02-19 3M Innovative Properties Company Ligand functionalized polymers
WO2011106583A1 (en) 2010-02-26 2011-09-01 Ventana Medical Systems, Inc. Polytag probes
EP2889625B1 (en) * 2010-03-03 2016-09-14 3M Innovative Properties Company Ligand guanidinyl functionalized polymers
CA2796087A1 (en) 2010-04-20 2011-10-27 Ventana Medical Systems, Inc. Two-color chromogenic in situ hybridization
EP2588144B1 (en) 2010-07-02 2018-05-09 Ventana Medical Systems, Inc. Detecting targets using mass tags and mass spectrometry
EP2606055B1 (en) 2010-08-16 2015-06-03 Ventana Medical Systems, Inc. Substrates for chromogenic detection and methods of use in detection assays and kits
CN103201627B (zh) 2010-11-08 2016-10-12 丹麦达科有限公司 组织学样品中单个靶标分子的定量
US10718777B2 (en) 2010-12-06 2020-07-21 Agilent Technologies, Inc. Combined histological stain
WO2012099364A2 (en) * 2011-01-17 2012-07-26 Lg Electronics Inc. Kit for amplifying detected signal in immunosensor and method for detecting target antigen using the same
US9562259B2 (en) 2011-03-14 2017-02-07 Ventana Medical Systems, Inc. Method of analyzing chromosomal inversions
US9366675B2 (en) 2011-04-19 2016-06-14 Dako Denmark A/S Method for enzyme-mediated signal amplification
KR20120128440A (ko) * 2011-05-17 2012-11-27 삼성전자주식회사 표적 물질 검출용 키트 및 이를 이용한 표적 물질 검출 방법
KR101316519B1 (ko) 2011-08-26 2013-10-08 충남대학교산학협력단 ＰＮＡ 전달을 위한 올리고-아스파라긴산(Ａｓｐ)-ＰＮＡ 함유 복합체
WO2013079606A1 (en) 2011-12-01 2013-06-06 Ventana Medical Systems, Inc. Automated dual stain of mirna and protein targets
CN102565383B (zh) * 2011-12-30 2013-12-11 吴坚 信号放大型免疫荧光探针及其制备方法和应用
WO2013108126A2 (en) 2012-01-16 2013-07-25 University Of Oslo Methyltransferases and uses thereof
AU2013211666B2 (en) * 2012-01-23 2015-09-03 Ventana Medical Systems, Inc Polymer stabilization of chromogen solutions
US20140134651A1 (en) * 2012-11-07 2014-05-15 Quanta Eqip, Llc Stable Discrete PEG Based Peroxidase Biological Conjugates
US9075055B2 (en) 2013-03-15 2015-07-07 Hycor Biomedical, Inc. Device and associated methods for performing luminescence and fluorescence measurements of a sample
KR102306490B1 (ko) 2013-03-15 2021-09-28 리제너론 파아마슈티컬스, 인크. 생물학적 활성 분자, 그의 접합체 및 치료 용도
SG11201601230RA (en) 2013-08-26 2016-03-30 Regeneron Pharma Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
KR102399005B1 (ko) 2014-03-11 2022-05-17 리제너론 파마슈티칼스 인코포레이티드 항-egfrviii 항체 및 그것의 용도
CN111233992B (zh) * 2014-04-04 2024-07-19 韦斯塔隆公司 人工活化的肽
CN104027816B (zh) * 2014-06-16 2015-07-01 西安交通大学 一种可去聚乙二醇化的共装载阿霉素和siRNA载体及其合成方法
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
AU2015326827B2 (en) 2014-10-02 2019-11-07 Ventana Medical Systems, Inc. Polymers and conjugates comprising the same
JP2018513360A (ja) 2015-03-16 2018-05-24 ヴェンタナ メディカル システムズ， インク． アンドロゲン受容体スプライス変異体を検出するための材料及び方法並びにその使用
CN107995912A (zh) 2015-03-27 2018-05-04 里珍纳龙药品有限公司 美登素类衍生物、其偶联物和使用方法
KR101721158B1 (ko) * 2015-06-01 2017-03-29 금호석유화학 주식회사 포토레지스트 미세패턴 형성용 조성물, 이의 제조 방법 및 이를 이용한 포토레지스트 미세패턴 형성방법
KR20180025865A (ko) 2015-07-06 2018-03-09 리제너론 파마슈티칼스 인코포레이티드 다중특이적 항원 결합 분자 및 이의 용도
US10143990B2 (en) * 2015-07-07 2018-12-04 Life Technologies Corporation Method of distributing discrete polymer networks
HK1251654A1 (zh) * 2015-07-17 2019-02-01 奥菲迪亚有限公司 用於处理基底表面的连接分子
CN107923915B (zh) 2015-08-28 2021-05-04 文塔纳医疗系统公司 使用经掩蔽的半抗原在福尔马林固定石蜡包埋的组织中的蛋白质邻近测定
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
MX390630B (es) 2016-01-25 2025-03-21 Regeneron Pharma Derivados de maitansinoide, conjugados de los mismos y metodos de uso.
AU2017229370B2 (en) 2016-03-08 2021-03-11 Ventana Medical Systems, Inc. Multiplexed immunohistochemistry using recombinant antibodies with epitope tags
CN105903025B (zh) * 2016-04-26 2018-12-11 浙江理工大学 一种毛竹纤维素基纳米口服药物载体的制备方法
US11352446B2 (en) 2016-04-28 2022-06-07 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
CN121021395A (zh) 2016-06-28 2025-11-28 文塔纳医疗系统公司 点击化学用于ihc和ish测定中的信号扩增的应用
JP7021126B2 (ja) 2016-06-28 2022-02-16 ヴェンタナ メディカル システムズ， インク． マルチ色素キノンメチド及びチラミドコンジュゲートによる発色性ｉｈｃ及びｉｓｈ染色のための新規の色
JP2019524687A (ja) 2016-07-01 2019-09-05 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 抗体薬物複合体およびこれを用いた治療方法
RS64691B1 (sr) 2016-09-23 2023-11-30 Regeneron Pharma Bispecifična anti-muc16-cd3 antitela i konjugati anti-muc16 sa lekom
AU2017331361B2 (en) 2016-09-23 2024-07-18 Regeneron Pharmaceuticals, Inc. Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof
AU2017359043B2 (en) 2016-11-08 2022-06-16 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
EP3541958A1 (en) 2016-11-15 2019-09-25 Ventana Medical Systems, Inc. Compositions and methods for prognosing and treating colorectal cancer
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
EP4060345A1 (en) 2016-12-19 2022-09-21 Ventana Medical Systems, Inc. Peptide nucleic acid conjugates
CN111065622A (zh) 2017-05-18 2020-04-24 里珍纳龙药品有限公司 双八氢菲羧酰胺类化合物及其蛋白质偶联物
KR20200007905A (ko) 2017-05-18 2020-01-22 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
CN110809583A (zh) 2017-06-07 2020-02-18 瑞泽恩制药公司 用于内化酶的组合物和方法
CA3080857A1 (en) 2017-11-07 2019-05-16 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
EP3727470B1 (en) 2017-12-18 2024-11-20 Ventana Medical Systems, Inc. Peptide nucleic acid conjugates
EA202091672A1 (ru) 2018-01-08 2021-02-01 Регенерон Фармасьютикалз, Инк. Стероиды и их антитело-конъюгаты
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
JP7328990B2 (ja) 2018-04-30 2023-08-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｈｅｒ２及び／またはａｐｌｐ２に結合する抗体及び二重特異性抗原結合分子、ならびにそれらのコンジュゲート及び使用
WO2019217591A1 (en) 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anti-msr1 antibodies and methods of use thereof
MX2020012350A (es) 2018-05-17 2021-01-29 Regeneron Pharma Anticuerpos anti-cd63, conjugados y usos de estos.
CN109187468B (zh) * 2018-09-10 2020-11-20 广西师范大学 一种用适配体介导掺氮碳点催化h2o2与tmb反应荧光光谱法测定水胺硫磷的方法
JP7455816B2 (ja) 2018-09-20 2024-03-26 ヴェンタナ メディカル システムズ， インク． クマリン系架橋試薬
CN109265364B (zh) * 2018-09-21 2021-02-02 中国烟草总公司郑州烟草研究院 一种二甲戊灵半抗原与抗原的制备及应用
CN109307775A (zh) * 2018-11-09 2019-02-05 郑州安图生物工程股份有限公司 一种量子点标记免疫球蛋白的方法
MY206542A (en) 2018-11-20 2024-12-20 Regeneron Pharma Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists
EP3898651A2 (en) 2018-12-21 2021-10-27 Regeneron Pharmaceuticals, Inc. Tubulysins and protein-tubulysin conjugates
CN113226470B (zh) 2018-12-21 2025-05-06 瑞泽恩制药公司 利福霉素类似物及其抗体-药物缀合物
CN109633151B (zh) * 2018-12-26 2022-03-11 西北农林科技大学 一种肠炎沙门氏菌检测方法、试纸条及应用
CN109738406B (zh) * 2019-01-03 2021-06-18 中南民族大学 一种定量测定儿茶素类物质的方法
KR102877468B1 (ko) 2019-01-08 2025-10-29 리제너론 파마슈티칼스 인코포레이티드 흔적이 없는 링커 및 이의 단백질-접합체
WO2020172475A1 (en) 2019-02-21 2020-08-27 Regeneron Pharmaceuticals, Inc. Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
CN109824645B (zh) * 2019-02-28 2020-10-27 中国农业大学 华法林半抗原和人工抗原及其制备方法与应用
CN111686826B (zh) * 2019-03-15 2023-05-23 国家纳米科学中心 分层结构的微流控芯片及其应用
CN113785184B (zh) 2019-05-14 2025-02-28 文塔纳医疗系统公司 包括生物学样品处理腔室的系统
CN110437455B (zh) * 2019-06-21 2022-02-01 北京利德曼生化股份有限公司 一种用于稳定固相化蛋白的高分子聚合物及其制备方法和应用
US12252582B2 (en) 2019-08-29 2025-03-18 University Of Delaware Biofunctional thiophene monomers and polymers thereof for electronic biomedical devices
KR20220063185A (ko) 2019-09-16 2022-05-17 리제너론 파마슈티칼스 인코포레이티드 면역-pet 영상화를 위한 방사성 표지된 met 결합 단백질
US11814428B2 (en) 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN110642743B (zh) * 2019-10-18 2021-01-01 中国农业大学 硝呋酚酰肼半抗原和人工抗原及其制备方法与应用
US20230061438A1 (en) 2019-12-18 2023-03-02 Roche Sequencing Solutions, Inc. Methods of sequencing by synthesis using a consecutive labeling scheme
JP2023511956A (ja) 2020-01-24 2023-03-23 レゲネロン ファーマシューティカルス，インコーポレーテッド タンパク質－抗ウイルス化合物コンジュゲート
WO2021174113A1 (en) 2020-02-28 2021-09-02 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind her2, and methods of use thereof
IL319200A (en) 2020-04-16 2025-04-01 Regeneron Pharma Antibody-drug conjugates prepared using Diels-Alder compression methods
JP2023533218A (ja) 2020-06-24 2023-08-02 レゲネロン ファーマシューティカルス，インコーポレーテッド ツブリシン及びタンパク質－ツブリシンコンジュゲート
US20220072141A1 (en) 2020-07-13 2022-03-10 Regeneron Pharmaceuticals, Inc. Protein-drug conjugates comprising camptothecin analogs and methods of use thereof
US20240295549A1 (en) * 2020-08-07 2024-09-05 Vital Biosciences Inc. Multiplexed analyte detection
WO2022056494A1 (en) 2020-09-14 2022-03-17 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof
KR20230095070A (ko) 2020-10-22 2023-06-28 리제너론 파마슈티칼스 인코포레이티드 항-fgfr2 항체 및 이의 사용 방법
CN116783485A (zh) 2021-01-15 2023-09-19 文塔纳医疗系统公司 储存稳定的笼状半抗原
CN113307863B (zh) * 2021-05-25 2022-12-16 华南农业大学 一种聚天冬氨酸及其盐类抗体的制备方法和应用
IL307947A (en) 2021-07-28 2023-12-01 Regeneron Pharma An antiviral compound of proteins
US20230414775A1 (en) 2021-12-29 2023-12-28 Regeneron Pharmaceuticals, Inc. Tubulysins and protein-tubulysin conjugates
JP2025502147A (ja) 2022-01-12 2025-01-24 リジェネロン ファーマシューティカルズ，インク． タンパク質中のグルタミン残基にコンジュゲートしたカンプトテシンアナログおよびその使用
WO2023137443A1 (en) 2022-01-14 2023-07-20 Regeneron Pharmaceuticals, Inc. Verrucarin a derivatives and antibody drug conjugates thereof
JP2025512735A (ja) 2022-03-11 2025-04-22 リジェネロン ファーマシューティカルズ，インク． Ｇｌｐ１ペプチド模倣体を含む抗ｇｌｐ１ｒ抗体係留型薬物コンジュゲートおよびその使用
WO2024002924A2 (en) 2022-06-28 2024-01-04 F. Hoffmann-La Roche Ag Fluorescent dyes with large stokes shift
WO2024020164A2 (en) 2022-07-21 2024-01-25 Firefly Bio, Inc. Glucocorticoid receptor agonists and conjugates thereof
KR20250128394A (ko) 2022-11-30 2025-08-27 리제너론 파마슈티칼스 인코포레이티드 Tlr7 작용제 및 이의 항체-약물-접합체
CN120752059A (zh) 2022-12-21 2025-10-03 瑞泽恩制药公司 用于adc缀合的拓扑异构酶i抑制剂的前药及其使用方法
WO2024168199A1 (en) 2023-02-09 2024-08-15 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates via inverse electron demand diels-alder reactions
WO2024229105A1 (en) 2023-05-02 2024-11-07 Regeneron Pharmaceuticals, Inc. Anti-human m-cadherin (cdh15) antibodies, conjugates, and uses thereof for delivery of genetic payloads to muscle cells
WO2025014533A1 (en) 2023-07-10 2025-01-16 Regeneron Pharmaceuticals, Inc. Anti-human cacng1 antibody-drug conjugates and uses thereof
WO2025096921A1 (en) 2023-11-03 2025-05-08 Regeneron Pharmaceuticals, Inc. Peptide acids as a glp1r agonist and antibody-drug conjugates thereof
WO2025117727A1 (en) 2023-11-29 2025-06-05 Regeneron Pharmaceuticals, Inc. Analogs of quinoxaline/quinoline cytotoxins, linker- payloads, protein-drug conjugates, and uses thereof
WO2025220405A1 (ja) * 2024-04-17 2025-10-23 第一工業製薬株式会社 複合粒子及びその製造方法

Family Cites Families (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1564604A (en) 1925-06-12 1925-12-08 Chas S Hodges Water wheel
US1889708A (en) 1930-09-04 1932-11-29 Gen Railway Signal Co Interlocking system for railroads
US3892530A (en) 1974-09-23 1975-07-01 Hoffmann La Roche Colorimetric and fluorometric method
US4230683A (en) 1978-08-09 1980-10-28 Abbott Laboratories Hapten conjugated antibody for antibody or antigen detection
US4495296A (en) 1979-05-21 1985-01-22 New York Blood Center, Inc. Labeled anti-hapten antibodies and their use as a universal reagent for solid phase radio- and/or enzyme-immunoassays
US4425427A (en) 1980-03-13 1984-01-10 Vitafin N.V. Simultaneous, kinetic, spectrophotometric analysis of blood serum for multiple components
US4469797A (en) * 1982-09-23 1984-09-04 Miles Laboratories, Inc. Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives
US4490473A (en) 1983-03-28 1984-12-25 Panab Labeled antibodies and methods
US4879224A (en) 1985-01-10 1989-11-07 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing human phospholipase inhibitor polypeptides
US5756696A (en) * 1986-01-16 1998-05-26 Regents Of The University Of California Compositions for chromosome-specific staining
US5447841A (en) * 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
US6280929B1 (en) * 1986-01-16 2001-08-28 The Regents Of The University Of California Method of detecting genetic translocations identified with chromosomal abnormalities
JPS62231170A (ja) * 1986-03-31 1987-10-09 Nitto Electric Ind Co Ltd 標識複合体
DE3836656A1 (de) * 1988-10-27 1990-05-03 Boehringer Mannheim Gmbh Neue digoxigenin-derivate und ihre verwendung
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5595707A (en) 1990-03-02 1997-01-21 Ventana Medical Systems, Inc. Automated biological reaction apparatus
US5225325A (en) * 1990-03-02 1993-07-06 Ventana Medical Systems, Inc. Immunohistochemical staining method and reagents therefor
JPH03254697A (ja) 1990-03-05 1991-11-13 Konica Corp 分析方法、それに使用する試薬及び分析素子
US5403747A (en) 1992-04-01 1995-04-04 Thomas Jefferson University Protein assay using microwave energy
US5350686A (en) 1992-04-16 1994-09-27 Pioneer Hi-Bred International, Inc. Microwave acceleration of enzyme-catalyzed modification of macromolecules
US5834202A (en) * 1992-08-04 1998-11-10 Replicon, Inc. Methods for the isothermal amplification of nucleic acid molecules
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5679582A (en) 1993-06-21 1997-10-21 Scriptgen Pharmaceuticals, Inc. Screening method for identifying ligands for target proteins
EP0708837B1 (en) 1993-07-13 2006-03-08 Abbott Laboratories Fluorescent polymer labeled conjugates and intermediates
US5661040A (en) 1993-07-13 1997-08-26 Abbott Laboratories Fluorescent polymer labeled conjugates and intermediates
US5731171A (en) * 1993-07-23 1998-03-24 Arch Development Corp. Sequence independent amplification of DNA
US5643761A (en) * 1993-10-27 1997-07-01 The Trustees Of Columbia University In The City Of New York Method for generating a subtracted cDNA library and uses of the generated library
US5487975A (en) * 1993-11-15 1996-01-30 Ventana Medical Systems, Inc. Biotin/avidin formulation
US5648211A (en) * 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
EP0772619B2 (en) * 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AU3559695A (en) * 1994-09-30 1996-04-26 Inex Pharmaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
GB9420355D0 (en) 1994-10-10 1994-11-23 Univ Nottingham Preparation of protein microspheres, films and coatings
US6057099A (en) 1994-12-02 2000-05-02 Intelligene Ltd. Detection of nucleic acid sequences
US5648245A (en) * 1995-05-09 1997-07-15 Carnegie Institution Of Washington Method for constructing an oligonucleotide concatamer library by rolling circle replication
US5684142A (en) 1995-06-07 1997-11-04 Oncor, Inc. Modified nucleotides for nucleic acid labeling
US5883081A (en) 1995-07-26 1999-03-16 The Regents Of The University Of California Isolation of novel HIV-2 proviruses
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
JP3974941B2 (ja) * 1995-11-21 2007-09-12 イェール ユニバーシティ 単分子セグメントの増幅および検出
DE19627290A1 (de) * 1996-07-06 1998-01-08 Boehringer Mannheim Gmbh Bestimmung von Analyten unter Verwendung zweier Markierungen
US6361944B1 (en) 1996-07-29 2002-03-26 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6582921B2 (en) 1996-07-29 2003-06-24 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses thereof
US6750016B2 (en) 1996-07-29 2004-06-15 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6506564B1 (en) 1996-07-29 2003-01-14 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
DE69718054T2 (de) * 1996-10-04 2003-07-17 Universitaet Heidelberg Verfahren zur aufreinigung von dns
US5952890A (en) * 1997-02-05 1999-09-14 Fox Enterprises, Inc. Crystal oscillator programmable with frequency-defining parameters
AU738513B2 (en) * 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US5994071A (en) * 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
DE69838294T2 (de) * 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
US6124120A (en) * 1997-10-08 2000-09-26 Yale University Multiple displacement amplification
US6322901B1 (en) 1997-11-13 2001-11-27 Massachusetts Institute Of Technology Highly luminescent color-selective nano-crystalline materials
US6358682B1 (en) * 1998-01-26 2002-03-19 Ventana Medical Systems, Inc. Method and kit for the prognostication of breast cancer
US6582962B1 (en) 1998-02-27 2003-06-24 Ventana Medical Systems, Inc. Automated molecular pathology apparatus having independent slide heaters
AU763354B2 (en) 1998-02-27 2003-07-17 Ventana Medical Systems, Inc. Automated molecular pathology apparatus having independent slide heaters
US6855559B1 (en) * 1998-09-03 2005-02-15 Ventana Medical Systems, Inc. Removal of embedding media from biological samples and cell conditioning on automated staining instruments
US20030211630A1 (en) 1998-02-27 2003-11-13 Ventana Medical Systems, Inc. Automated molecular pathology apparatus having independent slide heaters
US6235480B1 (en) 1998-03-13 2001-05-22 Promega Corporation Detection of nucleic acid hybrids
ES2284247T3 (es) * 1998-04-03 2007-11-01 University Of Iowa Research Foundation Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos.
US6855552B2 (en) * 1998-09-03 2005-02-15 Ventana Medical Systems Automated immunohistochemical and in situ hybridization assay formulations
US7550298B2 (en) * 1998-09-03 2009-06-23 Ventana Medical Systems, Inc. Automated immunohistochemical and in situ hybridization assay formulations
DE69938353T2 (de) 1998-09-24 2009-03-05 Indiana University Research and Technology Corp., Indianapolis Wasserlösliche lumineszente quantum-dots sowie deren biokonjugate
US6414133B1 (en) * 1998-10-13 2002-07-02 Ventana Medical Systems, Inc. Multiple fusion probes
US7569344B2 (en) * 1998-10-26 2009-08-04 Ventana Medical Systems, Inc. Detection of human papilloma virus in papanicolaou (Pap) smears
US6432320B1 (en) 1998-11-02 2002-08-13 Patrick Bonsignore Refrigerant and heat transfer fluid additive
JP3847983B2 (ja) 1998-11-06 2006-11-22 株式会社三菱化学ヤトロン 免疫学的分析用試薬、免疫学的分析方法及び免疫学的分析用キット
US6699973B1 (en) 1998-11-19 2004-03-02 Elan Corporation, Plc Antibodies to peptides that target GIT receptors and related methods
EP1149175A2 (en) 1999-01-11 2001-10-31 President And Fellows Of Harvard College Isothermal amplification of dna
WO2000049049A1 (en) 1999-02-19 2000-08-24 Michigan State University An antigen test to detect equine protozoal myeloencephalitis in horse serum and cerebrospinal fluid
US6696304B1 (en) 1999-02-24 2004-02-24 Luminex Corporation Particulate solid phase immobilized protein quantitation
US6544798B1 (en) * 1999-02-26 2003-04-08 Ventana Medical Systems, Inc. Removal of embedding media from biological samples and cell conditioning on automated staining instruments
US6673214B1 (en) 1999-04-09 2004-01-06 Rocky Mountain Biosystems, Inc. Energy enhanced reaction catalysis and uses thereof
JP2002541482A (ja) 1999-04-13 2002-12-03 ヴィレックス アクチェンゲゼルシャフト 診断及び治療のためのウロキナーゼレセプターに対する抗体の使用
US6180349B1 (en) 1999-05-18 2001-01-30 The Regents Of The University Of California Quantitative PCR method to enumerate DNA copy number
US6409774B1 (en) 1999-06-11 2002-06-25 Resolution Sciences Corporation Electrophoresis-assisted staining of materials
DE19933701A1 (de) 1999-07-19 2001-01-25 Wilex Biotechnology Gmbh Zyklische peptidomimetische Urokinaserezeptorantagonisten
WO2001029265A1 (en) * 1999-10-15 2001-04-26 Ventana Medical Systems, Inc. Method of detecting single gene copies in-situ
US20060275784A1 (en) 1999-10-26 2006-12-07 Ventana Medical Systems, Inc. Detection of Human Papilloma Virus in Papanicolaou (Pap) Smears
CA2397417A1 (en) * 2000-01-12 2001-07-19 Sarah S. Bacus Method for quantitating a protein by image analysis
JP2004501340A (ja) 2000-01-13 2004-01-15 ナノスフェアー　インコーポレイテッド オリゴヌクレオチドを付着させたナノ粒子とその使用方法
WO2001071354A2 (en) 2000-03-20 2001-09-27 Massachusetts Institute Of Technology Inorganic particle conjugates
AU5352901A (en) * 2000-04-14 2001-10-30 Ventana Med Syst Inc Method for quantification of akt protein expression
US6291187B1 (en) * 2000-05-12 2001-09-18 Molecular Staging, Inc. Poly-primed amplification of nucleic acid sequences
US6828097B1 (en) * 2000-05-16 2004-12-07 The Childrens Mercy Hospital Single copy genomic hybridization probes and method of generating same
JP2004523201A (ja) 2000-05-16 2004-08-05 ザ チルドレンズ マーシー ホスピタル シングルコピーゲノムのハイブリダイゼーションプローブおよびその作製方法
US6794362B1 (en) 2000-05-30 2004-09-21 Connective Tissue Imagineering Llc Asparagine containing elastin peptide analogs
US7763421B2 (en) * 2000-06-05 2010-07-27 Ventana Medical Systems, Inc. Methods for producing nucleic acid hybridization probes that amplify hybridization signal by promoting network formation
US6323009B1 (en) * 2000-06-28 2001-11-27 Molecular Staging, Inc. Multiply-primed amplification of nucleic acid sequences
US6447692B1 (en) 2000-08-04 2002-09-10 Hrl Laboratories, Llc Nanometer sized phase change materials for enhanced heat transfer fluid performance
US6942970B2 (en) * 2000-09-14 2005-09-13 Zymed Laboratories, Inc. Identifying subjects suitable for topoisomerase II inhibitor treatment
US20040209303A1 (en) 2000-10-03 2004-10-21 Martin Mark T. Methods and compositions for directed microwave chemistry
US6649138B2 (en) * 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
US6576291B2 (en) 2000-12-08 2003-06-10 Massachusetts Institute Of Technology Preparation of nanocrystallites
EP1342075B1 (en) 2000-12-11 2008-09-10 President And Fellows Of Harvard College Device contaning nanosensors for detecting an analyte and its method of manufacture
US20020083888A1 (en) * 2000-12-28 2002-07-04 Zehnder Donald A. Flow synthesis of quantum dot nanocrystals
US20030022166A1 (en) * 2001-01-19 2003-01-30 Colin Collins Repeat-free probes for molecular cytogenetics
US6656685B2 (en) * 2001-01-29 2003-12-02 Ventana Medical Systems, Inc. Hybridization buffers using low molecular weight dextran sulfate and methods for their use
WO2003004944A2 (en) 2001-01-30 2003-01-16 Materials And Electrochemical Research (Mer) Corporation Nano carbon materials for enhancing thermal transfer in fluids
DE10105912A1 (de) 2001-02-09 2002-08-14 Roche Diagnostics Gmbh Rekombinante Proteinase K
CA2439477C (en) * 2001-02-27 2014-04-15 Virco Bvba Circular probe amplification (cpa) using energy-transfer primers
US6670113B2 (en) * 2001-03-30 2003-12-30 Nanoprobes Enzymatic deposition and alteration of metals
WO2002088670A1 (en) * 2001-04-30 2002-11-07 Ventana Medical Systems, Inc. Method and composition for staining microorganisms
WO2002088396A2 (en) * 2001-04-30 2002-11-07 Ventana Medical Systems, Inc. Reagents and methods for automated in situ or microarray hybridization
US6638722B2 (en) * 2001-06-13 2003-10-28 Invitrogen Corporation Method for rapid amplification of DNA
WO2003000853A2 (en) 2001-06-20 2003-01-03 Caprion Pharmaceuticals Inc. Protein aggregation assays and uses thereof
ATE556845T1 (de) 2001-07-20 2012-05-15 Life Technologies Corp Lumineszierende nanopartikel und ihre herstellung
US20030066998A1 (en) 2001-08-02 2003-04-10 Lee Howard Wing Hoon Quantum dots of Group IV semiconductor materials
US6977148B2 (en) * 2001-10-15 2005-12-20 Qiagen Gmbh Multiple displacement amplification
US6617137B2 (en) * 2001-10-15 2003-09-09 Molecular Staging Inc. Method of amplifying whole genomes without subjecting the genome to denaturing conditions
US20030165485A1 (en) 2001-11-09 2003-09-04 Goran Bertilsson Functional role and potential therapeutic use of Reelin, Gas6 and Protein S in relation to adult neural stem or progenitor cells
WO2003048317A2 (en) 2001-11-30 2003-06-12 Children's Hospital Medical Center Antibodies to magmas and uses thereof
US20050019901A1 (en) 2002-01-31 2005-01-27 Evgenia Matveeva Methods for synthesis of bio-active nanoparticles and nanocapsules for use in optical bio-disc assays and disc assembly including same
ATE364143T1 (de) * 2002-02-26 2007-06-15 Degima Medizinprodukte Gmbh Gewindevorrichtung mit verbessertem widerstand gegen durch torsion verursachtes brechen
US20040248151A1 (en) * 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
US7285289B2 (en) 2002-04-12 2007-10-23 Nagy Jon O Nanoparticle vaccines
US20040057958A1 (en) * 2002-05-17 2004-03-25 Waggoner David W. Immunogenicity-enhancing carriers and compositions thereof and methods of using the same
US7476442B2 (en) 2002-07-17 2009-01-13 Massachusetts Institute Of Technology Nanoparticle chains and preparation thereof
US7200252B2 (en) * 2002-10-28 2007-04-03 Ventana Medical Systems, Inc. Color space transformations for use in identifying objects of interest in biological specimens
JP2006504937A (ja) 2002-10-31 2006-02-09 シェモメテック・アクティーゼルスカブ 粒子の評価方法
US20040101822A1 (en) 2002-11-26 2004-05-27 Ulrich Wiesner Fluorescent silica-based nanoparticles
GB0227738D0 (en) 2002-11-28 2003-01-08 Univ Liverpool Nanoparticle conjugates and method of production thereof
US20040115727A1 (en) 2002-12-11 2004-06-17 Allergan, Inc., A Corporation Evolved clostridial toxins with altered protease specificity
US7056471B1 (en) 2002-12-16 2006-06-06 Agency For Science Technology & Research Ternary and quarternary nanocrystals, processes for their production and uses thereof
US20040170954A1 (en) 2003-02-10 2004-09-02 Mckenney Keith Pathogen inactivation assay
US20040229300A1 (en) 2003-04-22 2004-11-18 Frederickson Christopher J. Zinc-based screening test and kit for early diagnosis of prostate cancer
US6944333B2 (en) * 2003-04-30 2005-09-13 Ventana Medical Systems, Inc. Color image compression via spectral decorrelation and elimination of spatial redundancy
US7981667B2 (en) 2003-05-07 2011-07-19 Indiana University Research And Technology Corporation Alloyed semiconductor quantum dots and concentration-gradient alloyed quantum dots, series comprising the same and methods related thereto
WO2004104557A2 (en) * 2003-05-19 2004-12-02 Ventana Medical Systems, Inc. Electrophoretic in situ tissue staining
US20050181394A1 (en) * 2003-06-20 2005-08-18 Illumina, Inc. Methods and compositions for whole genome amplification and genotyping
US7642064B2 (en) * 2003-06-24 2010-01-05 Ventana Medical Systems, Inc. Enzyme-catalyzed metal deposition for the enhanced detection of analytes of interest
US7632652B2 (en) * 2003-06-24 2009-12-15 Ventana Medical Systems, Inc. Enzyme-catalyzed metal deposition for the enhanced in situ detection of immunohistochemical epitopes and nucleic acid sequences
KR100657891B1 (ko) * 2003-07-19 2006-12-14 삼성전자주식회사 반도체 나노결정 및 그 제조방법
US20050048498A1 (en) * 2003-08-29 2005-03-03 Applera Corporation Compositions, methods, and kits for assembling probes
KR100571817B1 (ko) 2003-09-19 2006-04-17 삼성전자주식회사 태그 서열에 혼성화하는 검출 프로브를 이용하는 표적핵산의 검출방법
JP2007506429A (ja) * 2003-09-23 2007-03-22 アトム・サイエンシズ・インコーポレーテッド ポリマー核酸のハイブリダイゼーションプローブ
WO2005047331A2 (en) 2003-11-07 2005-05-26 Immunex Corporation Antibodies that bind interleukin-4 receptor
WO2005064018A2 (en) * 2003-12-22 2005-07-14 Ventana Medical Systems, Inc. Microwave mediated synthesis of nucleic acid probes
TW200526224A (en) 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
US7104313B2 (en) 2003-12-31 2006-09-12 Intel Corporation Apparatus for using fluid laden with nanoparticles for application in electronic cooling
JP4579836B2 (ja) * 2004-01-23 2010-11-10 株式会社グリーンペプタイド 上皮細胞増殖因子受容体（ｅｇｆｒ）由来ペプチド
US7244665B2 (en) * 2004-04-29 2007-07-17 Micron Technology, Inc. Wafer edge ring structures and methods of formation
JP2007535944A (ja) * 2004-05-04 2007-12-13 ヴェンタナ メディカル システムズ インコーポレイテッド ｉｎｓｉｔｕハイブリダイゼーションのための内部対照
US20060110744A1 (en) * 2004-11-23 2006-05-25 Sampas Nicolas M Probe design methods and microarrays for comparative genomic hybridization and location analysis
US20060160116A1 (en) * 2004-12-16 2006-07-20 The Regents Of The University Of California Repetitive sequence-free DNA libraries
US8679484B2 (en) * 2005-03-02 2014-03-25 Polyrizon Ltd. Method for removal of toxins from mucosal membranes
US20060246524A1 (en) * 2005-04-28 2006-11-02 Christina Bauer Nanoparticle conjugates
US7615800B2 (en) 2005-09-14 2009-11-10 Eastman Kodak Company Quantum dot light emitting layer
EP3095467B1 (en) 2005-11-23 2020-05-06 Ventana Medical Systems, Inc. Antibody-enzyme conjugate
AU2006332806B2 (en) 2005-12-30 2012-03-15 Ventana Medical Systems, Inc. Na+, K+-ATPase expression in cervical dysplasia and cancer
EP3260863B1 (en) * 2006-05-27 2021-03-10 Fluidigm Canada Inc. Method for performing multiplex analysis of two or more analytes
EP2069537B1 (en) 2006-09-01 2011-08-31 Ventana Medical Systems, Inc. Method for producing nucleic acid probes
DK2078197T3 (da) * 2006-11-01 2016-05-23 Ventana Med Syst Inc Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåde til deres fremstilling og anvendelse
US7682789B2 (en) 2007-05-04 2010-03-23 Ventana Medical Systems, Inc. Method for quantifying biomolecules conjugated to a nanoparticle
EP2150858A4 (en) * 2007-05-14 2013-01-02 Solulink Inc NOVEL HYDRAZONE AND OXIMIC-BASED FLUORESCENT AND CHROMOPHORES / PRO-FLUORESCENT AND PRO-CHROMOPHORES REAGENTS AND LINES
EP3561513A1 (en) * 2007-05-23 2019-10-30 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
US20100291593A1 (en) * 2007-07-13 2010-11-18 Powell William C Method of identifying diagnostic reagents

Also Published As

Publication number Publication date
JP2010528285A (ja) 2010-08-19
JP2019197071A (ja) 2019-11-14
JP6770150B2 (ja) 2020-10-14
JP6473381B2 (ja) 2019-02-20
EP2167963B1 (en) 2019-04-17
EP3561513A1 (en) 2019-10-30
AU2008262489A1 (en) 2008-12-18
US9103822B2 (en) 2015-08-11
US20150309039A1 (en) 2015-10-29
US9017954B2 (en) 2015-04-28
US20110244544A1 (en) 2011-10-06
US20080305497A1 (en) 2008-12-11
CA2687178C (en) 2014-02-04
US20140243236A1 (en) 2014-08-28
US9575067B2 (en) 2017-02-21
US8486620B2 (en) 2013-07-16
AU2008262489B2 (en) 2013-11-28
US7985557B2 (en) 2011-07-26
JP2015179091A (ja) 2015-10-08
EP2167963A2 (en) 2010-03-31
ES2731432T3 (es) 2019-11-15
AU2008262489A2 (en) 2010-01-07
WO2008153744A2 (en) 2008-12-18
US20110245098A1 (en) 2011-10-06
CA2687178A1 (en) 2008-12-18
US8445191B2 (en) 2013-05-21
US20130273565A1 (en) 2013-10-17
WO2008153744A3 (en) 2009-07-16
JP2017198699A (ja) 2017-11-02
US20110244545A1 (en) 2011-10-06

Similar Documents

Publication Publication Date Title
DK2167963T3 (da) Polymerbærere til immunhistokemi og in situ-hybridisering
BRPI0807225A2 (pt) Dispositivo e método endocirúrgico
DK2079355T3 (da) Fremgangsmåde og system til brilleordination
BRPI0816907A2 (pt) Método e dispositivo
BRPI0812509A2 (pt) Aparelho reformador e método
BRPI0918958A2 (pt) dispositivo móvel, e, método
NL2002105A1 (nl) Improved Navigation Device and Method.
FR2921407B1 (fr) Preleveur statique multi-niveaux
DK2985941T3 (da) Fremgangsmåde og indretning til forbedrede statusrapporter
BRPI0913752A2 (pt) método, dispositivo, e, estrutura
DK2518655T3 (da) Anordning og fremgangsmåde til forebyggelse af hypoglykæmi
BRPI0809573A2 (pt) composição, e, método
DK2271933T3 (da) System og fremgangsmåde til cellekarakterisering
DK2337837T3 (da) Alpha-amylase-blandinger og fremgangsmåder til anvendelse heraf
BRPI0919687A2 (pt) calha, aparelho de classificação, e, aparelho de inspeção
DK2131939T3 (da) Filteranordning og fremgangsmåde
DK2204002T3 (da) Anordning og fremgangsmåde til databehandling
DK2231231T3 (da) Indføringssystem og indføringsindretning
DK2192933T3 (da) Materialer til oftalmologisk og ortorhinolaryngologisk anordning
DK2066817T3 (da) Molekylære afbrydere og fremgangsmåder til anvendelse deraf
DK2309938T3 (da) Kryokirurgiske systemer og fremgangsmåder til anvendelse heraf
BRPI0814167A2 (pt) Composição, e, método
DK2227535T3 (da) Fremgangsmåde og indretning til ølfremstilling
EP2147554A4 (en) DEVICE AND METHOD FOR DECODING BIT TRAIN
DK2006237T3 (da) Fremgangsmåde og system til optimering af containere i en blok